A Comparison of in vivo Tumor-Homing Abilities of Placental-Derived and Bone Marrow-Derived Mesenchymal Stromal Cells in High-Risk Neuroblastoma
Topic overview
This study evaluates placental-derived versus bone marrow-derived mesenchymal stromal cells as potential cellular delivery vehicles for treating high-risk neuroblastoma in children. Using an orthotopic xenograft model, researchers compared the tumor-homing capabilities of both MSC types to determine which shows superior targeting for future therapeutic applications.
Key takeaways
- Mesenchymal stromal cells possess innate tumor-homing properties that may enable targeted cellular therapy delivery in neuroblastoma
- Placental-derived MSCs and bone marrow-derived MSCs were compared for tumor-homing efficacy in orthotopic neuroblastoma models
- MSC-based delivery vehicles represent a novel therapeutic approach for high-risk neuroblastoma in pediatric patients
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. A Comparison of in vivo Tumor-Homing Abilities of Placental-Derived and Bone Marrow-Derived Mesenchymal Stromal Cells in High-Risk Neuroblastoma. GlobalCastMD Medical Library. 2024-09-21. https://dev.library.globalcastmd.com/article/9190?via_space=staycurrentmd
Comments